Clinical Trial Outcomes part of Ramucirumab : a promising development in advanced non-small cell lung cancer

2014 The VEGF pathway is a critical target for anti-angiogenic therapy in advanced nonsmall cell lung cancer (NSCLC). Bevacizumab, a monoclonal antibody targeting VEGF-A, is the only anti-angiogenic agent approved for first-line use in combination with platinum-based chemotherapy. Ramucirumab is another monoclonal antibody that specifically binds to the… CONTINUE READING